Treatment with the PRMT5 inhibitor EPZ015666 results in a decrease of MYC protein levels and medulloblastoma cell growth, which suggests that PRMT5 inhibitors are potential therapeutics for MYC- and MYCN-driven cancers. The gene discussed is MYCN; the disease is medulloblastoma.